Krill Oil: EPA, DHA, Phospholipids, and Label Guide

Krill oil is obtained from small marine crustaceans. Health Canada’s current monograph recognizes oil from Euphausia superba and Euphausia pacifica and treats EPA and DHA as the relevant declared fatty-acid potencies. ¹

Brands use krill oil to provide EPA and DHA in an oil that is rich in phospholipids. Products can also declare phosphatidylcholine, choline, or astaxanthin. Those details can help describe the preparation, but none should replace the EPA and DHA amounts when the goal is to compare long-chain omega-3 content. ²

A front label may emphasize 1,000 mg of krill oil while the Supplement Facts panel discloses much smaller EPA and DHA amounts. That does not make the label internally inconsistent. EPA and DHA are parts of the oil, not alternative names for its full mass.

If the label states only total krill oil, the product-specific EPA and DHA payload is unknown. Do not estimate it from another brand, a generic average, a named raw material, capsule color, or a claim that the oil is concentrated.

NIH notes that omega-3s in krill oil occur primarily as phospholipids. Some studies suggest somewhat higher bioavailability than fish-oil omega-3s, while other studies do not. The evidence does not support a blanket claim that every lower-dose krill oil is equivalent or superior to every fish-oil product. ²

One randomized single-dose crossover study in 15 healthy adults reported higher 72-hour EPA and DHA exposure after krill oil than after the tested fish oil when the EPA and DHA doses were matched. That is a preparation-specific pharmacokinetic result from a small acute study, not proof of a better clinical outcome or a universal conversion factor between products. ³

Krill oil can contain the carotenoid astaxanthin, and some products state an amount while others mention it only in marketing copy. Preserve a separately disclosed amount in micrograms or milligrams rather than assuming that every krill oil supplies the same amount.

Astaxanthin is often described as an antioxidant, but its presence does not prove that the finished oil is fresh, stable, or protected from oxidation. Those questions require product-specific handling, storage, and analytical results. Do not use capsule color as an astaxanthin assay or an oxidation test.

Krill oil, fish oil, and algal oil can all provide long-chain omega-3s, but their source, fatty-acid profile, carrier form, capsule count, allergens, and accessory constituents differ. A source name alone does not tell you which product supplies more EPA, more DHA, or a better-matched serving.

Long-chain omega-3 evidence is not one universal result. EPA and DHA can lower triglycerides, but heart-event, inflammation, joint, cognition, and general wellness claims do not all have the same evidence or use the same formulations. A retail krill-oil softgel should not borrow every result from high-dose prescription omega-3 trials. ²

A pooled analysis of two randomized, double-blind, placebo-controlled trials in 520 adults with severe hypertriglyceridemia tested 4 g per day of a novel krill-derived omega-3 phospholipid and free-fatty-acid formulation for 26 weeks. The formulation reduced fasting triglycerides more than placebo at 12 and 26 weeks. The trials were sponsored by the company developing the formulation. This does not establish that a typical lower-dose consumer krill-oil supplement will produce the same result, treat severe hypertriglyceridemia, or replace clinical care. ⁴

Health Canada’s 2025 monograph illustrates why the active amount matters: its authorized claim thresholds are written around the daily EPA and DHA provided, not around a large front-label krill-oil number alone. These are Canadian licensing conditions, not a universal personal dose or a prediction that a product will work. ¹

Marine oils are oxidation-sensitive. Health Canada’s monograph requires finished-product specifications for peroxide, anisidine, and TOTOX values and requires testing for specified marine-oil contaminants in its licensing context. A consumer label may not show the actual batch results. ¹

Phrases such as third-party tested, purified, sustainably sourced, traceable, or freshness guaranteed are starting points, not test results. Stronger evidence is a current, lot-linked document that names the method, limit, and measured result. A certification mark should be checked with the certifying body and for the exact product or supply chain it covers.

Krill are crustaceans, so shellfish-allergen context matters. Health Canada’s monograph includes shellfish in its example allergen labeling when applicable and advises stopping use if allergy occurs. A krill-oil label cannot establish individual suitability for someone with a crustacean-shellfish allergy. ¹

Omega-3 supplements can cause mild gastrointestinal effects and can be relevant to anticoagulant monitoring, especially at higher intakes or alongside medicines that affect clotting. NIH notes that most research does not show clinically significant bleeding at commonly studied fish-oil doses, so this should be handled as a medication-context question rather than a blanket bleeding claim. ²

Health Canada’s monograph advises consultation before use during pregnancy or breastfeeding and sets a 4.1 g daily krill-oil ceiling for products using that monograph. This is a Canadian product licensing limit, not a formal omega-3 UL, a personal target, or a reason to ignore the separate EPA and DHA amounts. ¹